SHENZHEN, China, July 9, 2021 /PRNewswire/ -- BGI is aware of reports in Reuters regarding the co***ny¡¯s non-invasive prenatal test (NIPT test) - NIFTY (Non-Invasive Fetal TrisomY).
BGI¡¯s NIPT tests (one kind of BGI gene test) have been used around the world to identify genetic conditions in pregnancy. These tests provide ***tors with the scientific basis to assist millions of pregnant women, leading to better health outcomes and, in some cases, saved lives.
The research that BGI has undertaken collaboratively with some of the world¡¯s leading academic and scientific institutions has led to major medical breakthroughs that will benefit the world for many decades to come.
As a leader in life science and gene technology, BGI is committed to improving health outcomes worldwide. That is and always has been the co***ny¡¯s mission. Assertions that BGI is motivated by anything other than the advancement of health outcomes are both deeply disappointing and factually incorrect.
These are the facts:
BGI has never been asked to provide, nor has it provided data from its NIFTY test to Chinese authorities for national security or national defense security purposes. |
Home
